Merck Included in 15 Dividend Stocks for Income Investment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy MRK?
Source: Yahoo Finance
- Rating Reaffirmed: On March 25, RBC reiterated its Outperform rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $142, indicating confidence in the company's future performance despite investor disappointment over the 'modest premium' for the acquisition of Terns Pharmaceuticals.
- Acquisition Feedback Analysis: Following a conference call discussing the proposed acquisition of Terns, RBC analyst Trung Huynh noted that investor feedback was largely negative, questioning why Terns would agree to sell a high-probability asset at what was described as a 'modest premium', reflecting market caution regarding the deal.
- Capital Allocation Recognition: Despite concerns over the acquisition, investors still view Merck as a savvy capital allocator capable of effectively addressing its upcoming patent cliff, indicating that the company's strategic position in the industry remains recognized.
- Potential Competitive Threats: There is an expectation that competing bidders may emerge or that shareholders could outright reject the deal, which could impact Merck's stock performance, necessitating close monitoring of subsequent developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to fall
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 120.290
Low
95.00
Averages
119.53
High
139.00
Current: 120.290
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MERCK & CO INC - ENLICITIDE SAFETY PROFILE ALIGNS WITH PRIOR TRIALS, NO SIGNIFICANT VARIATIONS IN ADVERSE EVENTS
Safety Profile Consistency: The safety profile of Merck's product is consistent with previous trials, indicating no significant changes in adverse events.
No Meaningful Differences: There are no meaningful differences in adverse events reported compared to earlier studies, suggesting stability in safety outcomes.
See More
MERCK & CO INC - FDA CHOOSES ENLICITIDE FOR COMMISSIONER'S NATIONAL PRIORITY VOUCHER IN DECEMBER 2025
Merck & Co. Announcement: Merck & Co. has selected Senlicitide for the position of Commissioner’s National Priority Voucher.
Vouchers Overview: The National Priority Voucher program is designed to incentivize the development of treatments for neglected diseases.
See More
Merck & Co Inc's Enlicitide Lowers LDL-C by 64.6% After Eight Weeks from Baseline
- Merck & Co. Announcement: Merck & Co. has reported a significant reduction in LDL-C levels by 64.6% from baseline after eight weeks of treatment.
- Clinical Implications: This reduction indicates a potentially effective treatment option for managing cholesterol levels in patients.
See More
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Greater LDL-C Reductions at Eight Weeks Compared to Recommended Oral Non-Statin Therapies When Used with Statins
Significant Findings: Merck's Senliciti demonstrated significantly greater LDL-C reductions at eight weeks compared to guideline-recommended oral non-statin therapies.
Study Context: The results were observed when Senliciti was added to background statin therapy, highlighting its potential effectiveness in cholesterol management.
See More
Merck Schedules Q1 2026 Earnings Call for April 30
- Earnings Call Scheduled: Merck will hold its Q1 2026 sales and earnings conference call on April 30 at 9:00 a.m. ET, where executives will provide an overview of the company's quarterly performance, aimed at enhancing investor confidence and transparency.
- Participation Details: Investors, journalists, and the public can access the live audiowebcast of the call via the provided link, with a replay and related financial disclosures available on the company’s website, ensuring broad dissemination and accessibility of information.
- Company Vision: Merck is committed to leveraging cutting-edge science to improve lives globally, with over 130 years of history focused on developing important medicines and vaccines, aspiring to be the premier research-intensive biopharmaceutical company, showcasing its strategic positioning in the industry.
- Forward-Looking Statements: The company’s release includes forward-looking statements that highlight potential risks and uncertainties, including industry competition, economic factors, and challenges in new product development, reminding investors to consider various factors that may affect actual results.
See More
FDA Poised to Allow Pharmacies to Sell Injectable Peptides
- Policy Shift Outlook: The FDA is likely to permit compounding pharmacies to sell injectable peptides again, a move that would be a victory for HHS Secretary Robert F. Kennedy Jr., despite opposition from many senior FDA officials regarding the safety of these products.
- Safety Risk Alerts: The FDA's updated list of banned peptides includes cesium chloride and chloral hydrate, with the former linked to irregular heartbeat and the latter associated with dosing errors and oversedation, highlighting significant safety concerns surrounding these substances.
- Regulatory Review Meeting: The FDA plans to schedule a meeting of its Pharmacy Compounding Advisory Committee to discuss medical evidence for the peptides and vote on whether to allow pharmacies to resume production, indicating a serious regulatory focus on product safety.
- Market Condition Analysis: Scott Brunner, CEO of the Alliance for Pharmacy Compounding, expressed concerns that consumers are likely purchasing unproven illicit products or research-grade items, as there are no pharmaceutical-grade versions available from FDA-registered manufacturers, illustrating the chaotic state of the market and lack of effective oversight.
See More
MERCK & CO INC - ENLICITIDE SAFETY PROFILE ALIGNS WITH PRIOR TRIALS, NO SIGNIFICANT VARIATIONS IN ADVERSE EVENTS
Safety Profile Consistency: The safety profile of Merck's product is consistent with previous trials, indicating no significant changes in adverse events.
No Meaningful Differences: There are no meaningful differences in adverse events reported compared to earlier studies, suggesting stability in safety outcomes.
See More
MERCK & CO INC - FDA CHOOSES ENLICITIDE FOR COMMISSIONER'S NATIONAL PRIORITY VOUCHER IN DECEMBER 2025
Merck & Co. Announcement: Merck & Co. has selected Senlicitide for the position of Commissioner’s National Priority Voucher.
Vouchers Overview: The National Priority Voucher program is designed to incentivize the development of treatments for neglected diseases.
See More
Merck & Co Inc's Enlicitide Lowers LDL-C by 64.6% After Eight Weeks from Baseline
- Merck & Co. Announcement: Merck & Co. has reported a significant reduction in LDL-C levels by 64.6% from baseline after eight weeks of treatment.
- Clinical Implications: This reduction indicates a potentially effective treatment option for managing cholesterol levels in patients.
See More
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Shows Greater LDL-C Reductions at Eight Weeks Compared to Recommended Oral Non-Statin Therapies When Used with Statins
Significant Findings: Merck's Senliciti demonstrated significantly greater LDL-C reductions at eight weeks compared to guideline-recommended oral non-statin therapies.
Study Context: The results were observed when Senliciti was added to background statin therapy, highlighting its potential effectiveness in cholesterol management.
See More
Merck Schedules Q1 2026 Earnings Call for April 30
- Earnings Call Scheduled: Merck will hold its Q1 2026 sales and earnings conference call on April 30 at 9:00 a.m. ET, where executives will provide an overview of the company's quarterly performance, aimed at enhancing investor confidence and transparency.
- Participation Details: Investors, journalists, and the public can access the live audiowebcast of the call via the provided link, with a replay and related financial disclosures available on the company’s website, ensuring broad dissemination and accessibility of information.
- Company Vision: Merck is committed to leveraging cutting-edge science to improve lives globally, with over 130 years of history focused on developing important medicines and vaccines, aspiring to be the premier research-intensive biopharmaceutical company, showcasing its strategic positioning in the industry.
- Forward-Looking Statements: The company’s release includes forward-looking statements that highlight potential risks and uncertainties, including industry competition, economic factors, and challenges in new product development, reminding investors to consider various factors that may affect actual results.
See More
FDA Poised to Allow Pharmacies to Sell Injectable Peptides
- Policy Shift Outlook: The FDA is likely to permit compounding pharmacies to sell injectable peptides again, a move that would be a victory for HHS Secretary Robert F. Kennedy Jr., despite opposition from many senior FDA officials regarding the safety of these products.
- Safety Risk Alerts: The FDA's updated list of banned peptides includes cesium chloride and chloral hydrate, with the former linked to irregular heartbeat and the latter associated with dosing errors and oversedation, highlighting significant safety concerns surrounding these substances.
- Regulatory Review Meeting: The FDA plans to schedule a meeting of its Pharmacy Compounding Advisory Committee to discuss medical evidence for the peptides and vote on whether to allow pharmacies to resume production, indicating a serious regulatory focus on product safety.
- Market Condition Analysis: Scott Brunner, CEO of the Alliance for Pharmacy Compounding, expressed concerns that consumers are likely purchasing unproven illicit products or research-grade items, as there are no pharmaceutical-grade versions available from FDA-registered manufacturers, illustrating the chaotic state of the market and lack of effective oversight.
See More
